TY - JOUR T1 - Taranto’s long shadow? Cancer mortality shows alarming peaks for specific types in the most polluted city of Italy but also in surrounding towns JF - medRxiv DO - 10.1101/2020.12.18.20248464 SP - 2020.12.18.20248464 AU - R. Roberto Cazzolla Gatti AU - Alena Velichevskaya Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/12/19/2020.12.18.20248464.abstract N2 - A national-scale study in Italy showed an incidence of cancer higher in the territories indicated as highly polluted compared to the regional average. One of them, the city of Taranto in Apulia (Italy), which is considered one of the most polluted cities in Europe, has numerous industrial activities that impact population health. We studied the epidemiological effects of a high level of pollution produced by the industrial area of Taranto in increasing the mortality rate for some specific cancer types in the city and towns of the two provinces located downwind. We analysed 10-year mortality rates for 14 major types of tumours reported among the residents of Taranto, of 6 surrounding towns, randomly placed within an imaginary cone in the main wind direction from the vertex of the industrial zone of Taranto. Our results confirm our hypothesis that the mortality rate for some specific types of cancer (namely, Hodgkin and non-Hodgkin lymphomas, leukaemia, liver and bladder tumours) are higher than the norm in the municipality of Taranto and we have evidence that other local causes may be implicated in the excess of mortality besides the potential dispersal of pollutants from the industrial area of Taranto. The proximity to the industrial area of Taranto cannot, therefore, explain alone the anomalies detected in some populations. It is likely that other site-specific sources of heavy pollution are playing a role in worsening the death toll of these towns and this must be taken into serious consideration by environmental policy-makers and local authorities.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding to declareAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We confirm all relevant ethical guidelines have been followed and no approval was needed by IRB and/or ethics committeeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used for this study are publicly available from ISTAT https://www.istat.it/it/archivio/4216 ER -